Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Ischemic Stroke-Pipeline Review, H1 2015

Acute Ischemic Stroke-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Ischemic Stroke-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Ischemic Stroke-Pipeline Review, H1 2015', provides an overview of the Acute Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Ischemic Stroke Overview 9

Therapeutics Development 10

Pipeline Products for Acute Ischemic Stroke-Overview 10

Pipeline Products for Acute Ischemic Stroke-Comparative Analysis 11

Acute Ischemic Stroke-Therapeutics under Development by Companies 12

Acute Ischemic Stroke-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Acute Ischemic Stroke-Products under Development by Companies 17

Acute Ischemic Stroke-Companies Involved in Therapeutics Development 19

AB Science 19

AstraZeneca PLC 20

Biogen, Inc. 21

D-Pharm Ltd. 22

Daiichi Sankyo Company, Limited 23

DiaMedica Inc. 24

Digna Biotech, S.L. 25

Genervon Biopharmaceuticals, LLC 26

Glucox Biotech AB 27

Grifols, S.A. 28

Lumosa Therapeutics Co., Ltd. 29

Mitsubishi Tanabe Pharma Corporation 30

Pharmicell Co., Ltd. 31

PhytoHealth Corporation 32

Remedy Pharmaceuticals, Inc. 33

Simcere Pharmaceutical Group 34

Stemedica Cell Technologies, Inc. 35

Acute Ischemic Stroke-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

3K3A-APC-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Cerecellgram-Stroke-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

DB-017-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

DM-199-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

DS-1040-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

glyburide-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

GM-602-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

HBN-1-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Human Plasmin-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

LT-3001-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

masitinib-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Mesenchymal Stem Cells-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MP-124-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

natalizumab-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

PHN-014-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Recombinant Plasmin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

SIM-071201-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

THR-18-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

ticagrelor-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Acute Ischemic Stroke-Recent Pipeline Updates 77

Acute Ischemic Stroke-Dormant Projects 100

Acute Ischemic Stroke-Discontinued Products 102

Acute Ischemic Stroke-Product Development Milestones 105

Featured News & Press Releases 105

Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 105

Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA 105

Nov 04, 2014: D-Pharm Reports First Results from its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with tPA 106

Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 106

Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 107

Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 107

Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 109

Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 109

Jan 08, 2014: D-Pharm receives grant to support the development of its Phase 2 product, THR-18 110

Dec 05, 2013: AstraZeneca announces initiation of two additional global studies for BRILINTA 110

Appendix 112

Methodology 112

Coverage 112

Secondary Research 112

Primary Research 112

Expert Panel Validation 112

Contact Us 112

Disclaimer 113

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H1 2015 10

Number of Products under Development for Acute Ischemic Stroke-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Acute Ischemic Stroke-Pipeline by AB Science, H1 2015 19

Acute Ischemic Stroke-Pipeline by AstraZeneca PLC, H1 2015 20

Acute Ischemic Stroke-Pipeline by Biogen, Inc., H1 2015 21

Acute Ischemic Stroke-Pipeline by D-Pharm Ltd., H1 2015 22

Acute Ischemic Stroke-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 23

Acute Ischemic Stroke-Pipeline by DiaMedica Inc., H1 2015 24

Acute Ischemic Stroke-Pipeline by Digna Biotech, S.L., H1 2015 25

Acute Ischemic Stroke-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 26

Acute Ischemic Stroke-Pipeline by Glucox Biotech AB, H1 2015 27

Acute Ischemic Stroke-Pipeline by Grifols, S.A., H1 2015 28

Acute Ischemic Stroke-Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 29

Acute Ischemic Stroke-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 30

Acute Ischemic Stroke-Pipeline by Pharmicell Co., Ltd., H1 2015 31

Acute Ischemic Stroke-Pipeline by PhytoHealth Corporation, H1 2015 32

Acute Ischemic Stroke-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 33

Acute Ischemic Stroke-Pipeline by Simcere Pharmaceutical Group, H1 2015 34

Acute Ischemic Stroke-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 35

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Stage and Target, H1 2015 38

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Acute Ischemic Stroke Therapeutics-Recent Pipeline Updates, H1 2015 77

Acute Ischemic Stroke-Dormant Projects, H1 2015 100

Acute Ischemic Stroke-Dormant Projects (Contd..1), H1 2015 101

Acute Ischemic Stroke-Discontinued Products, H1 2015 102

Acute Ischemic Stroke-Discontinued Products (Contd..1), H1 2015 103

Acute Ischemic Stroke-Discontinued Products (Contd..2), H1 2015 104

List of Figures

Number of Products under Development for Acute Ischemic Stroke, H1 2015 10

Number of Products under Development for Acute Ischemic Stroke-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Top 10 Targets, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 37

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AstraZeneca PLC

Biogen, Inc.

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Genervon Biopharmaceuticals, LLC

Glucox Biotech AB

Grifols, S.A.

Lumosa Therapeutics Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Pharmicell Co., Ltd.

PhytoHealth Corporation

Remedy Pharmaceuticals, Inc.

Simcere Pharmaceutical Group

Stemedica Cell Technologies, Inc.

Acute Ischemic Stroke Therapeutic Products under Development, Key Players in Acute Ischemic Stroke Therapeutics, Acute Ischemic Stroke Pipeline Overview, Acute Ischemic Stroke Pipeline, Acute Ischemic Stroke Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com